Roche won't boost Illumina offer without negotiating; OptiMedica gets good news in EU on Catalys;

@FierceMedDev: Siemens Manufacturing Plant Leaning Towards Collaboration With NHS Delegation. Item | Follow @FierceMedDev

> Roche ($RHHBY) says it would consider any argument to boost its $6.7 billion offer for Illumina ($ILMN) if the company would start negotiating, but has no plans to do so otherwise. Release

> Sunnyvale, CA-based OptiMedica has received CE Mark approval for its Catalys precision laser system for creating single-plane and multi-plane arc cuts/incisions in the cornea during cataract surgery. OptiMedica release

> Rosetta Genomics, a maker of microRNA-based molecular diagnostics, raised $1.38 million in a registered direct offering. The company plans to use the funds for "general corporate purposes." Release

> Optos has tapped Financial Times Group financial director Louisa Burdett as its next CFO. Her name may be familiar, as she played a key role during the merger of Glaxo and SmithKline. She also has served as CFO at General Electric Healthcare's medical diagnostics business. News

> 3M's Infection Prevention Division will team up with Sage Products to offer surgical staff and patients a new preoperative prepping kit to help address surgical site infection risk within three main reservoirs of bacteria. 3M release

> Novian Health has begun a multicenter clinical trial for Novilase interstitial laser therapy in malignant breast tumors. Novilase ILT is an image-guided, minimally invasive alternative for lumpectomy. Release

And Finally... A woman is suing Wright Medical after her hip joint replacement allegedly popped out of its socket and caused further damage to her leg. Article

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.